Adults 21 to 80, any sex, with Glaucoma, Open-Angle. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Mean Retinal Sensitivity From Two MachinesPrimary· three hours
Mean (Average) retinal sensitivity to light as measured in decibels in multiple spots across the central and peripheral retina (entire visual field). Higher numbers translate to dimmer light which when detected means better vision.
Global field from Humphrey Visual Field
Group
Value
95% CI
Healthy Controls
29.9
± 1.4
Glaucoma Group
24.8
± 3.9
Global field from VisuALL
Group
Value
95% CI
Healthy Controls
28.7
± 1.3
Glaucoma Group
22.9
± 4.9
Inferior nasal quadrant from Humphrey Visual Field
Group
Value
95% CI
Healthy Controls
30.3
± 1.3
Glaucoma Group
24.8
± 5.8
Inferior nasal quadrant from VisuALL
Group
Value
95% CI
Healthy Controls
28.7
± 1.6
Glaucoma Group
23.3
± 6.9
Superior hemifield from Humphrey Visual Field
Group
Value
95% CI
Healthy Controls
29.5
± 1.5
Glaucoma Group
23.7
± 5.0
Superior hemifield from VisuALL
Group
Value
95% CI
Healthy Controls
28.6
± 1.6
Glaucoma Group
21.8
± 6.5
Global Correlation (Agreement Between Two Machines in the Overall Visual Field)Primary· three hours
Correlation (Agreement) between Humphrey Visual Field and VisuALL retinal sensitivity as measured by mean deviation (light measurement in decibels) in multiple spots across the central and peripheral retina (entire visual field). This is the amount of agreement of the measure threshold, which is the lowest level of light detected in different points across the visual field (overall), between two testing machines.
Group
Value
95% CI
Healthy Controls
0.5
0 – 1
Glaucoma Group
0.8
0 – 1
Inferior Nasal Quadrant Correlation (Agreement Between Two Machines in the Inferior Nasal Visual Field)Secondary· three hours
Correlation (Agreement) between Humphrey Visual Field and VisuALL retinal sensitivity as measured by mean deviation (light measurement in decibels) in multiple spots across the inferior nasal visual field. This is the amount of agreement of the measure threshold, which is the lowest level of light detected in different points across the inferior (lower) nasal portion of the visual field, between two testing machines.
Group
Value
95% CI
Healthy Controls
0.3
0 – 1
Glaucoma Group
0.8
0 – 1
Superior Hemifield Correlation (Agreement Between Two Machines in the Superior Hemifield Visual FieldSecondary· three hours
Correlation (Agreement) between Humphrey Visual Field and VisuALL retinal sensitivity as measured by mean deviation (light measurement in decibels) in multiple spots across the superior (upper) hemifield portion of the visual field. This is the amount of agreement of the measure threshold, which is the lowest level of light detected in different points across the visual field in the superior hemifield, between two testing machines.
Group
Value
95% CI
Healthy Controls
0.4
0 – 1
Glaucoma Group
0.6
0 – 1
Sponsor's own description
To determine age-adjusted reference values of the visuALL Field Analyzer (vFA) retinal sensitivity and to assess the repeatability of the measured values and compare them with those measured by a Standard Automatic Perimetry (SAP).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Other trials of Standard Automatic Perimetry Humphrey Field Analyzer
Trials testing the same drug.
NCT05325996 — Evaluating Home Testing Devices for the Management of Glaucoma
· NA
· completed
Other recruiting trials for Glaucoma, Open-Angle
Currently open trials in the same condition.
NCT06964191 — Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
· Phase 2
· recruiting
NCT06240312 — Optic Nerve Head Strain as Biomarker for Glaucoma
· NA
· recruiting
NCT05405868 — Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial
· Phase 3
· recruiting
NCT05710198 — Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma
· Phase 3
· recruiting
NCT06058598 — Exercise Training in Patients With Glaucoma
· NA
· active not recruiting
Other Wills Eye trials
Trials by the same sponsor.
NCT05660447 — A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR
· Phase 2, PHASE3
· active not recruiting
NCT05325996 — Evaluating Home Testing Devices for the Management of Glaucoma
· NA
· completed
NCT06130384 — Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.
· Phase 4
· completed
NCT04784234 — Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin
· NA
· terminated
NCT04459949 — Comparative Study of Sharkskin Versus Grieshaber Forceps During ILM Peeling
· NA
· unknown
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wills Eye
Last refreshed: 29 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03804684.